For decades, ultrasound has been used to image organs such as the heart and kidneys, check blood flow, monitor the development of fetuses, reduce pain and even break up kidney stones.
Now, a Norwegian biotech company called Phoenix Solutions AS is working with the Translational Genomics Research Institute (TGen), a Phoenix, Arizona-based biomedical research facility, to test the use of these pulsed sound waves to direct and focus cancer drug therapies.
In laboratory tests, TGen will help analyze the effectiveness of a technology called Acoustic Cluster Therapy (ACT), a unique approach to targeting cancer cells by concentrating the delivery of chemotherapies, making them more effective and potentially reducing their toxicity.
Humanscan Co. Ltd., a South Korean manufacture of ultrasound diagnostic imaging, is developing clinically applicable hardware optimized for ACT, which TGen will then validate.
Phoenix Solutions is using funding from Innovation Norway to conduct this research in advance of pancreatic cancer clinical trials planned later this year.
“We are very pleased to receive this grant, which will enable us to develop and validate an optimal ultrasound platform for clinical use of ACT. In their respective fields, Humanscan and TGen both represent the cutting edge of science, and we are confident this will contribute to the clinical success of our program,” said Dr. Per Sontum, CEO of Phoenix Solutions.
TGen is a world leader in the development of novel therapeutics for the treatment of pancreatic cancer. The TGen team led the clinical development of one of the current standard-of-care regimens for this disease — nab-paclitaxel plus gemcitabine. TGen currently is involved in 13 pancreatic cancer clinical programs.
“We are pleased that this research program has become a reality, and look forward to working with ACT. The concept represents a novel approach to targeted drug delivery and looks very promising,” said Dr. Haiyong Han, a Professor in TGen’s Molecular Medicine Division and head of the Basic Research Unit in TGen’s Pancreatic Cancer Program.
Among the advantages of ultrasound technology: it is generally painless; non-invasive; does not require needles, injections or incisions; and patients are not exposed to ionizing radiation, making the procedure safer than diagnostic techniques such as X-rays and CT scans.
Humanscan CEO Sungmin Rhim said, “We are excited to enter into this collaboration with Phoenix (Solutions) and participate in the development of ACT. Ultrasound mediated, targeted drug delivery is an emerging therapy approach with great potential and we are delighted to be in the forefront of this development.”
Phoenix Solutions also is considering this technology for use in addressing other types of cancer, including: liver, prostate and triple-negative breast cancer; and other diseases, including those involving inflammation and the central nervous system.
The Latest on: Cancer drug delivery
via Google News
The Latest on: Cancer drug delivery
- Stakeholders Address Innovative Strategies Driving Cancer Outcomes in New Jerseyon September 21, 2022 at 9:20 am
Key stakeholders involved in the delivery of cancer care in New Jersey discuss strategies driving innovation in oncology and remaining challenges impeding their integration at the 70th Annual Roy A.
- FDA approves new treatment for breast cancer subtype HER2-lowon September 20, 2022 at 11:28 am
In early August, the U.S. Food and Drug Administration approved of a new treatment option called Enhertu for unresectable or metastatic HER2-low breast cancer. This is the first targeted therapy ...
- Molecular delivery system developed at URI shows promise against bladder canceron September 19, 2022 at 10:18 am
A research team from the University of Rhode Island and The Miriam Hospital in Providence has demonstrated a potential new weapon in the fight against bladder cancer.
- Can diet change the course of cancer?on September 17, 2022 at 12:49 pm
Unlimited access to C&EN’s daily news coverage on cen.acs.org Weekly delivery of the C&EN ... approaches that complement cancer medicines. Many cancer drugs add just a few months to a patient ...
- Research team creates more effective cancer therapyon September 14, 2022 at 12:30 pm
Various approaches for treating lymph node metastasis exist. But now, a research team has combined two forms of therapy to create a superior treatment method than conventional chemotherapy.
- Effective Drug Delivery Topic for Hybrid Oxford Science Cafeon September 14, 2022 at 8:32 am
By Edwin B. Smith University of Mississippi A University of Mississippi professor will discuss the effective delivery of drugs during the first Oxford Science Cafe of the fall semester. The talk is ...
- "Glass Bubble" Nanocarrier Delivers Effective Combination Therapy for Pancreatic Canceron September 14, 2022 at 1:53 am
Researchers have developed nanoscale particles to deliver a combination of two drugs to pancreatic tumors in a mouse model of pancreatic cancer, outperforming either drug delivered separately. ...
- Cancer-fighting particle packs drugs in a glass bubble coreon September 13, 2022 at 5:00 pm
Additionally, the dual-delivery approach proved more effective than either of the drugs delivered on their own via nanocarrier, and recruited more cancer-killing immune cells and maintained drug ...
- ‘Glass bubble’ nanocarrier boosts effects of combination therapy for pancreatic canceron September 12, 2022 at 5:00 pm
Improving drug delivery. Custom-designed nanoparticles that deliver drugs directly to tumors can avoid the toxicity of traditional chemotherapy. Crafting a ‘combo’ carrier. Researchers designed an ...
via Bing News